Christos N. Papandreou

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Christos N. Papandreou, Danai Daliani, Darrell Nix et al. · Journal of Clinical Oncology · 2004 · 436 citations · Full text

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

Shi‐Ming Tu, Randall E. Millikan, Bayabel Mengistu et al. · The Lancet · 2001 · 395 citations

Urology, Surgical Oncology, Genitourinary Cancer +8

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook et al. · Journal of Hepatology · 2016 · 376 citations · Full text

Observational Registry, Pediatric Epidemiology, Clinical Population +10